Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780275 | 0.87 | PDE2A (0.47) | PDE2ACES2GSK3BGAAAKR1C3 | |
| SCHEMBL14054398 | 0.82 | GSK3B (0.50) | PDE2ACES2GSK3BGAAKDM4E | |
| SCHEMBL5744377 | 0.80 | CES2 (0.57) | CES2MDM2 | |
| SCHEMBL7532012 | 0.79 | PDE2A (0.51) | PDE2ACES2GSK3BGAAKDM4E | |
| SCHEMBL29786688 | 0.78 | CES2 (0.52) | PDE2ACES2GAADDR1KDM4E | |
| SCHEMBL2073688 | 0.78 | CES2 (0.52) | PDE2ACES2GAADDR1KDM4E | |
| SCHEMBL2302131 | 0.76 | CES2 (0.47) | PDE2ACES2GAAAKR1C3AKR1C2 | |
| SCHEMBL12516836 | 0.76 | NPSR1 (0.57) | PDE2ACES2DDR1TMPRSS4TRPV1 | |
| SCHEMBL15745421 | 0.76 | CES2 (0.50) | PDE2ACES2GAADDR1KDM4E | |
| SCHEMBL43771 | 0.75 | ALDH1A1 (0.59) | CES2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | PDE2A 3489/4885CES2 3644/4885GSK3B 546/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | PDE2A 3489/4885CES2 3644/4885GSK3B 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.